Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IKT-001 · 2 trials · 2 indications
The number of participants who experience a TEAE, serious TEAE or TEAE of special interest will be reported.
Change in Pulmonary Vascular Resistance (PVR)
Change in 6-minute walk distance (6MWD)
| Arm | Type | Description |
|---|---|---|
| IKT-001 | EXPERIMENTAL | IKT-001 tablets for PO administration |
| Placebo | PLACEBO_COMPARATOR | Matching placebo to IKT-001 tablets for PO administration |
| Name | Type | Description |
|---|---|---|
| IKT-001 | DRUG | IKT-001 tablets for PO administration |
| Placebo | DRUG | Placebo to IKT-001 tablets for PO administration |
Inclusion Criteria: * Capable of giving signed informed consent. * Participants who have completed Study IKT-001-201 or any other Phase 2 or 3 controlled clinical study with IKT-001. Exclusion Criteria: * Any of the following clinical laboratory values at screening: * ALT or AST levels \>3× th...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 5 | PHASE3 | selexipag, Macitentan |
| Merck & Co., Inc. | MRK | 8 | PHASE3 | Sotatercept, Riociguat, Frespaciguat |
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag, Tyvaso (treprostinil) |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606, LIQ861 Treprostinil, LIQ861 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | Levosimendan (TNX-103) |
| Inhibikase Therapeutics, Inc. | IKT | 2 | PHASE3 | IKT-001 |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Tectonic Therapeutic Inc | TECX | 2 | PHASE2 | TX45 |
| Gossamer Bio, Inc. | GOSS | 1 | PHASE3 | Seralutinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| IRulya Therapeutics Inc. | IRLA | 1 | PHASE2 | LAM-001 |
| GSK plc Sponsored ADR | GSK | 2 | PHASE1 | HS235 |
IKT-001 is an investigational small molecule being developed for the treatment of pulmonary arterial hypertension (PAH), a cardiovascular condition. It is in Phase 3 clinical development and has received an orphan drug designation from the FDA. It is not yet approved for commercial use.
IKT-001 targets BCR-ABL, a protein. By acting on this molecular target, the drug is being studied as a potential therapy for pulmonary arterial hypertension. It is a small molecule therapeutic candidate developed by Inhibikase Therapeutics.
IKT-001 is being developed by Inhibikase Therapeutics, Inc., which trades under the ticker IKT. The company is advancing the drug through Phase 3 clinical development for pulmonary arterial hypertension, a cardiovascular indication.
IKT-001 is in Phase 3 clinical development for pulmonary arterial hypertension. It is an investigational therapy and has not been approved by the FDA. The program includes two active Phase 3 trials with a combined planned enrollment of 970 participants.
IKT-001 is being evaluated in two Phase 3 trials. NCT07365332 is an adaptive program in pulmonary arterial hypertension that is currently recruiting across multiple countries. NCT07632898 is an open-label study in PAH that is not yet recruiting. Both trials enroll adults aged 18 and older.
IKT-001 is not FDA approved. It remains an investigational drug in Phase 3 clinical development for pulmonary arterial hypertension. The FDA has granted it an orphan drug designation, which is a status that supports development of therapies for rare diseases.